IPCALAB2020-04-012020-06-30in-bse-fin:OneOperatingExpenses01Member IPCALAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares IPCALAB 2020-04-01 2021-03-31 2020-07-29 INR Crores First quarter Single segment Pharmaceuticals 2020-04-01 2020-06-30 Unaudited Consolidated 15344000000.00 120900000.00 15464900000.00 3720000000.00 679300000.00 -82900000.00 2563300000.00 27400000.00 510300000.00 2581100000.00 9998500000.00 5466400000.00 0.00 5466400000.00 1029800000.00 -30900000.00 998900000.00 0.00 4467500000.00 0.00 0.00 0.00 -10700000.00 4456800000.00 -31200000.00 4425600000.00 4461300000.00 -4500000.00 4430000000.00 -4400000.00 252700000.00 2 35.27 35.24 0.00 0.00 35.27 35.24 0.00 0.00 0.00 Notes:ttt n1tThe above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 10, 2020.The Statutory Auditors have carried out the limited review of the results. nttt n2tBeing manufacturers of pharmaceuticals and providers of essential services, the Group is continuing with its manufacturing and marketing operations strictly following the Covid-19 related guidelines issued by the government from time to time. The Group has considered possible impact of Covid-19 on the carrying amounts of property, plant and equipments, investments, inventories, receivables and other current assets. The Group expects that the carrying amounts of the assets are recoverable and that the Group will continue to have sufficient liquidity to finance its business operations as well as expansion plans. However, a definitive assessment of Covid-19 impact, at this stage, is not possible in view of uncertain economic environment. nttt n3tThe Group has only one operating segment viz. 'Pharmaceuticals'.t nttt n4tThe figures for the quarter ended March 31, 2020 are the balancing figures between audited figures in respect of the full financial year 2019-20 and the published year to date unaudited figures upto December 31, 2019. n5tFigures of the previous periods have been regrouped wherever necessary. other expenses 2581100000.00